The Epidermolysis Bullosa Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Epidermolysis Bullosa Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Epidermolysis Bullosa Market.
Some of the key takeaways from the Epidermolysis Bullosa Pipeline Report:
- Companies across the globe are diligently working toward developing novel Epidermolysis Bullosa treatment therapies with a considerable amount of success over the years.
- Epidermolysis Bullosa companies working in the treatment market are Phoenicis Therapeutics, Zikani Therapeutics, BioMendics, LLC, BPGbio Inc., InMed Pharmaceuticals Inc, Phoenix Tissue Repair, Inc, Castle Creek Biosciences, LLC, RHEACELL, Abeona Therapeutics, Inc., and others, are developing therapies for the Epidermolysis Bullosa treatment
- Emerging Epidermolysis Bullosa therapies in the different phases of clinical trials are- PTD 003, ZKN 013, TolaSure, BP 31510, INM-755, PTR-01, FCX-007, ABCB5+ MSCs, EB 101, and others are expected to have a significant impact on the Epidermolysis Bullosa market in the coming years.
- In March 2023, “A Phase 3b Study for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) in New and Previously EB-101 Treated Patients” is the name of the experiment that Abeona Therapeutics, Inc. started. A multicenter, open-label, single-arm Phase 3b safety research aimed at treating RDEB wounds in roughly 10–12 patients by using up to 8 autologous, gene-corrected keratinocyte sheets (EB-101) once during surgery.
- In November 2022, Positive topline results from the pivotal Phase 3 VIITALTM research, which evaluated the safety and effectiveness of EB-101 for the treatment of individuals with recessive dystrophic epidermolysis bullosa (RDEB), were released by Abeona Therapeutics Inc. In large chronic RDEB wounds, the VIITALTM research demonstrated statistically significant, clinically meaningful improvements in wound healing and pain reduction, meeting both of its co-primary efficacy goals.
Epidermolysis Bullosa Overview
A class of uncommon disorders known as epidermolysis bullosa is characterized by brittle, blistering skin. Blisters can develop in reaction to slight trauma, including those caused by heat, rubbing, scraping, or adhesive tape.
Get a Free Sample PDF Report to know more about Epidermolysis Bullosa Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/epidermolysis-bullosa-pipeline-insight
Emerging Epidermolysis Bullosa Drugs Under Different Phases of Clinical Development Include:
- PTD 003: Phoenicis Therapeutics
- ZKN 013: Zikani Therapeutics
- TolaSure: BioMendics, LLC
- BP 31510: BPGbio Inc.
- INM-755: InMed Pharmaceuticals Inc
- PTR-01: Phoenix Tissue Repair, Inc
- FCX-007: Castle Creek Biosciences, LLC
- ABCB5+ MSCs: RHEACELL
- EB 101: Abeona Therapeutics, Inc.
Epidermolysis Bullosa Route of Administration
Epidermolysis Bullosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Epidermolysis Bullosa Molecule Type
Epidermolysis Bullosa Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Epidermolysis Bullosa Pipeline Therapeutics Assessment
- Epidermolysis Bullosa Assessment by Product Type
- Epidermolysis Bullosa By Stage and Product Type
- Epidermolysis Bullosa Assessment by Route of Administration
- Epidermolysis Bullosa By Stage and Route of Administration
- Epidermolysis Bullosa Assessment by Molecule Type
- Epidermolysis Bullosa by Stage and Molecule Type
DelveInsight’s Epidermolysis Bullosa Report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Epidermolysis Bullosa product details are provided in the report. Download the Epidermolysis Bullosa pipeline report to learn more about the emerging Epidermolysis Bullosa therapies
Epidermolysis Bullosa Pipeline Analysis:
The Epidermolysis Bullosa pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Epidermolysis Bullosa with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Epidermolysis Bullosa Treatment.
- Epidermolysis Bullosa key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Epidermolysis Bullosa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Epidermolysis Bullosa market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Epidermolysis Bullosa drugs and therapies
Epidermolysis Bullosa Pipeline Market Drivers
- Increasing prevalence of Epidermolysis bullosa, increasing Clinical trials for the treatment of Epidermolysis Bullosa are some of the important factors that are fueling the Epidermolysis Bullosa Market.
Epidermolysis Bullosa Pipeline Market Barriers
- However, high cost associated with the treatment and diagnosis of Epidermolysis bullosa, side effects associated with the treatment and other factors are creating obstacles in the Epidermolysis Bullosa Market growth.
Scope of Epidermolysis Bullosa Pipeline Drug Insight
- Coverage: Global
- Key Epidermolysis Bullosa Companies: Phoenicis Therapeutics, Zikani Therapeutics, BioMendics, LLC, BPGbio Inc., InMed Pharmaceuticals Inc, Phoenix Tissue Repair, Inc, Castle Creek Biosciences, LLC, RHEACELL, Abeona Therapeutics, Inc., and others
- Key Epidermolysis Bullosa Therapies: PTD 003, ZKN 013, TolaSure, BP 31510, INM-755, PTR-01, FCX-007, ABCB5+ MSCs, EB 101, and others
- Epidermolysis Bullosa Therapeutic Assessment: Epidermolysis Bullosa current marketed and Epidermolysis Bullosa emerging therapies
- Epidermolysis Bullosa Market Dynamics: Epidermolysis Bullosa market drivers and Epidermolysis Bullosa market barriers
Request for Sample PDF Report for Epidermolysis Bullosa Pipeline Assessment and clinical trials
Table of Contents
1. Epidermolysis Bullosa Report Introduction
2. Epidermolysis Bullosa Executive Summary
3. Epidermolysis Bullosa Overview
4. Epidermolysis Bullosa- Analytical Perspective In-depth Commercial Assessment
5. Epidermolysis Bullosa Pipeline Therapeutics
6. Epidermolysis Bullosa Late Stage Products (Phase II/III)
7. Epidermolysis Bullosa Mid Stage Products (Phase II)
8. Epidermolysis Bullosa Early Stage Products (Phase I)
9. Epidermolysis Bullosa Preclinical Stage Products
10. Epidermolysis Bullosa Therapeutics Assessment
11. Epidermolysis Bullosa Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Epidermolysis Bullosa Key Companies
14. Epidermolysis Bullosa Key Products
15. Epidermolysis Bullosa Unmet Needs
16 . Epidermolysis Bullosa Market Drivers and Barriers
17. Epidermolysis Bullosa Future Perspectives and Conclusion
18. Epidermolysis Bullosa Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services